http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an... http://pharmalicensing.com/redirs/news_rss//public/news/view/496739/0/11/depomed-reports-results-from-two-phase-3-clinical-trials-evaluating-non-hormonal-therapy-for-menopausal-hot-flashes http://pharmalicensing.com/redirs/news_rss//public/news/view/496739/0/11/depomed-reports-results-from-two-phase-3-clinical-trials-evaluating-non-hormonal-therapy-for-menopausal-hot-flashes Danish Medicines Agency, 2 October 2009--We have updated section 5.1 Contraception in the Guideline for applications for authorisation of clinical trials of medicinal products in humans. http://pharmalicensing.com/redirs/news_rss//public/news/view/496767/0/11/changed-definition-of-safe-contraception-in-clinical-trials http://pharmalicensing.com/redirs/news_rss//public/news/view/496767/0/11/changed-definition-of-safe-contraception-in-clinical-trials